Clinical Trial Update: LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib [Phase 3]

View source ↗

Summary

A Phase III global trial update (LOGiC) evaluated chemotherapy plus lapatinib in HER2-positive gastric cancer, with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Lapatinib (Lapatinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Neoplasms, Gastrointestinal Tract | Phase 3 | Status: COMPLETED | Results posted: 2013-10-29